Adage Capital Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$128M Buy
916,513
+75,348
+9% +$10.6M 0.2% 97
2025
Q4
$103M Sell
841,165
-514,083
-38% -$62.5M 0.16% 123
2025
Q3
$150M Sell
1,355,248
-97,984
-7% -$11.1M 0.24% 74
2025
Q2
$161M Buy
1,453,232
+133,080
+10% +$14.2M 0.27% 61
2025
Q1
$148M Sell
1,320,152
-393,978
-23% -$40.7M 0.27% 68
2024
Q4
$158M Buy
+1,714,130
New +$154M 0.28% 60
2024
Q2
Sell
-101,387
Closed -$7.43M 896
2024
Q1
$7.43M Buy
+101,387
New +$7.8M 0.01% 650
2023
Q3
Sell
-1,246,588
Closed -$96.1M 898
2023
Q2
$96.1M Sell
1,246,588
-385,596
-24% -$30.8M 0.21% 118
2023
Q1
$135M Buy
1,632,184
+75,500
+5% +$6.25M 0.3% 77
2022
Q4
$134M Buy
1,556,684
+585,707
+60% +$46.4M 0.32% 63
2022
Q3
$59.9M Sell
970,977
-119,300
-11% -$7.52M 0.15% 160
2022
Q2
$67.4M Buy
1,090,277
+898,300
+468% +$55.6M 0.15% 137
2022
Q1
$11.4M Sell
191,977
-818,800
-81% -$52.3M 0.02% 659
2021
Q4
$73.4M Buy
1,010,777
+961,300
+1,943% +$66.2M 0.13% 162
2021
Q3
$3.46M Sell
49,477
-569,300
-92% -$40M 0.01% 866
2021
Q2
$42.6M Buy
618,777
+556,200
+889% +$37.1M 0.08% 250
2021
Q1
$4.04M Sell
62,577
-1,400
-2% -$90.3K 0.01% 820
2020
Q4
$3.73M Sell
63,977
-231,000
-78% -$13.9M 0.01% 714
2020
Q3
$18.6M Buy
+294,977
New +$20.5M 0.05% 394
2020
Q2
Sell
-1,112,325
Closed -$83.2M 765
2020
Q1
$83.2M Sell
1,112,325
-151,100
-12% -$10.4M 0.25% 104
2019
Q4
$82.1M Sell
1,263,425
-78,000
-6% -$5.08M 0.2% 132
2019
Q3
$85M Sell
1,341,425
-14,200
-1% -$928K 0.21% 122
2019
Q2
$91.6M Buy
1,355,625
+81,100
+6% +$5.34M 0.23% 117
2019
Q1
$82.9M Sell
1,274,525
-302,700
-19% -$20.1M 0.21% 124
2018
Q4
$98.7M Buy
1,577,225
+51,731
+3% +$3.62M 0.27% 104
2018
Q3
$118M Sell
1,525,494
-92,600
-6% -$6.99M 0.26% 101
2018
Q2
$115M Sell
1,618,094
-137,896
-8% -$9.74M 0.26% 95
2018
Q1
$132M Buy
1,755,990
+292,330
+20% +$23.2M 0.31% 84
2017
Q4
$105M Sell
1,463,660
-165,600
-10% -$12.6M 0.24% 114
2017
Q3
$132M Sell
1,629,260
-145,232
-8% -$11.1M 0.32% 77
2017
Q2
$126M Sell
1,774,492
-175,600
-9% -$11.7M 0.31% 78
2017
Q1
$132M Buy
1,950,092
+26,000
+1% +$1.83M 0.33% 75
2016
Q4
$138M Sell
1,924,092
-224,100
-10% -$16.7M 0.38% 69
2016
Q3
$170M Buy
2,148,192
+489,155
+29% +$39.7M 0.47% 49
2016
Q2
$138M Sell
1,659,037
-80,500
-5% -$7.14M 0.38% 77
2016
Q1
$160M Buy
1,739,537
+258,807
+17% +$23.3M 0.43% 64
2015
Q4
$150M Sell
1,480,730
-198,600
-12% -$20.7M 0.39% 72
2015
Q3
$165M Sell
1,679,330
-482,400
-22% -$53.6M 0.46% 53
2015
Q2
$253M Buy
2,161,730
+146,000
+7% +$16M 0.63% 29
2015
Q1
$198M Sell
2,015,730
-384,000
-16% -$39M 0.48% 43
2014
Q4
$226M Sell
2,399,730
-612,200
-20% -$63.3M 0.55% 37
2014
Q3
$321M Sell
3,011,930
-217,750
-7% -$21.3M 0.79% 15
2014
Q2
$268M Sell
3,229,680
-1,579,814
-33% -$123M 0.69% 26
2014
Q1
$341M Buy
4,809,494
+650,500
+16% +$51M 0.93% 13
2013
Q4
$312M Buy
4,158,994
+282,000
+7% +$19.6M 0.83% 15
2013
Q3
$244M Sell
3,876,994
-957,000
-20% -$57.2M 0.7% 22
2013
Q2
$248M Buy
+4,833,994
New +$252M 0.76% 18

Other funds holding GILD

Adage Capital Partners's GILD Position: Q1 2026 in Review

Adage Capital Partners increased its Gilead Sciences (GILD) stake by 9% in Q1 2026, buying an estimated $10.6M and bringing the position to 916,513 shares worth $128M. The position accounts for 0.2% of the portfolio, ranked #97.

Adage Capital Partners first reported a position in GILD in Q2 2013 and has held it in 47 quarters since. The position peaked at $341M in Q1 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Adage Capital Partners held 916,513 shares of Gilead Sciences worth $128M as of Q1 2026.
  • Adage Capital Partners bought 75,348 Gilead Sciences shares in Q1 2026, an estimated $10.6M.
  • Gilead Sciences made up 0.2% of Adage Capital Partners's portfolio in Q1 2026, its #97 holding.
  • Adage Capital Partners first reported a position in Gilead Sciences in Q2 2013 and has held it in 47 quarters since.
  • Adage Capital Partners's Gilead Sciences position peaked at $341M in Q1 2014.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.